NovoCure (NVCR) Notes Payables (2024 - 2025)
NovoCure's (NVCR) quarterly Notes Payables came in at $560.6 million in Q3 2025, up 0.59% year-on-year from $557.3 million in Q3 2024, and little changed quarter-over-quarter from $559.8 million in Q2 2025.
NovoCure (NVCR) Notes Payables (2024 - 2025) Analysis & Trends
NovoCure has disclosed Notes Payables across 2 years of filings, most recently posting $560.6 million for Q3 2025.
- Notes Payables for Q3 2025 came in at $560.6 million, up 0.59% year-over-year; the trailing twelve-month figure through Sep 2025 was $560.6 million (up 0.59% YoY), and the FY2024 annual result was $558.2 million, changed N/A from the prior year.
- Notes Payables came in at $560.6 million for Q3 2025 at NovoCure, roughly flat from $559.8 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $560.6 million in Q3 2025 to a low of $557.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | NovoCure | 1.63 Bn | 1.20 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 560.62 Mn |
| Jun 30, 2025 | 559.79 Mn |
| Mar 31, 2025 | 558.97 Mn |
| Dec 31, 2024 | 558.16 Mn |
| Sep 30, 2024 | 557.33 Mn |